Pfizer booster has 95.3% efficacy against COVID-19 relative to two doses
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
The Pfizer booster has an efficacy of 95.3 per cent relative to the first two doses, according to the company's ongoing Phase 3 trial results. The randomised controlled trial followed 5000 double-dosed people who received the booster, and 5000 who received a placebo, about 10 months after their initial vaccinations. The researchers say among those who hadn't previously had COVID-19, six boosted participants tested positive during the trial compared to 123 placebo participants. The trial took place when Delta was the dominant COVID-19 variant.
Journal/conference: New England Journal of Medicine
Link to research (DOI): 10.1056/NEJMoa2200674
Organisation/s: Pfizer, USA
Funder: Funded by BioNTech and Pfizer; C4591031 ClinicalTrials.gov number, NCT04955626.
Attachments:
Note: Not all attachments are visible to the general public
